$23.26 0.00 (0.00%) Portola Pharmaceuticals Inc - NASDAQ

Sep. 27, 2016 | 04:00 PM
Last Trade: 23.26
Trade Time: Sep 27 04:00 PM Eastern Daylight Time
Change: +0.00 (0.00%)
Prev Close: 23.26
Open: 22.81
Bid: 22.71
Ask: 38.80
  1. No results found.
  1. Portola Pharmaceuticals Announces Andexanet Alfa and Cerdulatinib Data Presentations at #ASH2015

    Benzinga | Dec. 5, 2015 | 10:28AM EST
  2. Portola Pharmaceuticals Announces FDA Grants Fast Track Designation to Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients

    Benzinga | Oct. 13, 2015 | 08:04AM EST
  3. Portola Pharma Reports Will Present Data on Dual Kinase Inhibitor Cerdulatinib at ASCO

    Benzinga | May. 18, 2015 | 08:05AM EST
  4. Portola Reports Q4 EPS -$0.82 Vs Est -$0.90, Announce Positive Phase 3 ANNEXA-R Study

    Benzinga | Mar. 2, 2015 | 08:05AM EST
  5. What Investors Should Expect From Portola Pharmaceutical's Upcoming Data Readouts

    Benzinga | Jan. 9, 2015 | 12:43PM EST
  6. Friday's Morning Movers: Earnings Start To Trickle In

    Benzinga | Jan. 9, 2015 | 10:06AM EST
  7. Portola Pharmaceuticals Announces Commercial Supply Agreement For Andexanet Alfa With Lonza

    Benzinga | Oct. 16, 2014 | 16:08PM EST
  8. Portola Pharmaceuticals Announces Proposed Offering of Common Stock For Gross Proceeds Of $160M

    Benzinga | Oct. 1, 2014 | 16:26PM EST
  9. Midday Gainers From October 1 - Angie's List Inc, Tekmira Pharmaceuticals Corporation And More

    Benzinga | Oct. 1, 2014 | 12:52PM EST
  10. Morning Market Movers

    Benzinga | Oct. 1, 2014 | 09:39AM EST
  11. Paulson Bets Again On Mallinckrodt

    GuruFocus | Aug. 7, 2014 | 11:02AM EST
  12. Top 4 Stocks In The Biotechnology Industry With The Highest EPS

    Benzinga | Jun. 25, 2014 | 04:54AM EST
  13. Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Bayer and Janssen for Phase 3 Studies of Andexanet Alfa*, Investigational Factor Xa Inhibitor Reversal Agent, and XARELTO(R)

    Benzinga | Feb. 3, 2014 | 08:02AM EST
  14. Portola Pharma Reports New Phase 2 Results Confirming Immediate, Dose-Dependent, Well-Tolerated Reversal of Anticoagulation Activity of XARELTO

    Benzinga | Dec. 9, 2013 | 11:04AM EST
  15. Portola Pharma Issues Results for First Phase 2 Trial Showing Extended Duration Infusion with PRT4445

    Benzinga | Oct. 14, 2013 | 17:06PM EST
Trading Center